What type of treatment is recommended for patients with right-sided infective endocarditis caused by methicillin-resistant bacteria?

For patients with right-sided infective endocarditis caused by methicillin-resistant bacteria, vancomycin is the recommended treatment. Vancomycin is a glycopeptide antibiotic that is effective against a range of gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA). This antibiotic is commonly used as the first-line treatment for serious infections when methicillin-resistant strains are suspected or confirmed, particularly in cases of endocarditis, due to its robust activity against these resistant organisms.

In the case of right-sided infective endocarditis, particularly affecting intravenous drug users, it is critical to have effective coverage against MRSA, which vancomycin provides. Additionally, vancomycin can penetrate the sites of infection effectively, ensuring that therapeutic levels are attained in the bloodstream and heart valves.

Other options, such as nafcillin, oxacillin, and daptomycin, are either ineffective against methicillin-resistant strains or not the first choice for MRSA-related infections in the context of endocarditis. Nafcillin and oxacillin are beta-lactam antibiotics that are not effective against methicillin-resistant Staphylococcus species, while daptomycin, although effective against MRSA, is typically reserved